Antimicrobial Resistance (AMR): Leveraging Biotech for a Solution

Author
Published on
Category

AMR, threatens more lives each year, disregarding borders, becoming a silent global pandemic. While awareness of AMR grows, the urgency, resources, and international collaboration needed for action remain lacking. Biotech experts aim to introduce innovative technologies, but face significant challenges. With global unity, we can expedite these solutions. HollandBIO urges to consider:

Secure funding for all stages of antibiotic development within the AMR domain.
Create incentives to ensure innovative products’ sustainability.
Explore models like subscription systems and rewards for milestones.
Ensure proper antibiotic use and facilitate diagnostics.

We, as a member of HollandBIO, not only support but also urge initiatives that foster these steps. 
AMR presents a looming crisis; biotech offers hope. The flawed antibiotic business model impedes progress. While the Netherlands advocates globally, tangible actions lag. Learning from other nations, we can unite and incentivize antibiotic innovation, safeguarding global health.
Starodub can assist developers of these innovative technologies with their development. Please reach out to find out how we can help.

Explore more Updates

Key Outcomes of LSH Dutch Mission to Japan: New Partnerships to Support Market Entry

Article 61(10) of MDR: A Pathway for Medical Device Software?

The Compliance Compass: Guiding Clinical Investigations for Medical Devices through ISO 14155 and MDR

Valentyna Starodub
Founder and Chief Executive Officer

Let's Connect

Talk to an expert